Neurogene(NGNE) - 2020 Q4 - Annual Report

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 10-K _________________________ (Exact name of registrant as specified in its charter) _________________________ ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) For the transition period from to Commission file number: 001-36327 _________________________ Neoleukin Therapeutics, Inc. (M ...